Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 21, Issue 34, Pages 5029-5033Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612821666150831141931
Keywords
Bone cancer pain; chemokine; chemokine receptor; therapeutic target
Categories
Funding
- National Natural Science Foundation of P.R. China [81400917]
- National Natural Science Foundation of Hubei Province [2014CFB449]
- Clinical Key Disciplines Construction Grant from the Ministry of Health of P.R. China
- Wuhan Municipal Human Resources and Social Security Bureau, Specialized Research Fund for the Doctoral Program of Higher Education [20130142120102, 2014QT021]
- Shenzhen Science and Technology Innovation Committee [GJHZ20130412153906741]
Ask authors/readers for more resources
Bone cancer pain (BCP) is still an intractable problem currently because the analgesic pharmacological intervention remains insufficient. Thus, the development of novel therapeutic target is critical for the treatment of BCP. Emerging evidence demonstrated that some chemokines and their receptors contribute to the induction and maintenance of BCP. In this article, we reviewed the current evidence for the role of different chemokines and their receptors (e.g. CXCL12/CXCR4, CXCL1/CXCR2, CCL2/CCR2, CCL5/CCR5, CX3CL1/CX3CR1 and CXCL10/CXCR3) in mediating BCP. By extensively understanding the involvement of chemokines and their receptors in BCP, novel therapeutic targets may be revealed for the treatment of BCP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
